🔗 Share this article Social Media Content Creators Driving Parallel Market for Unapproved Slimming Medication An underground market for unapproved slimming medications is being driven by TikTok fitness influencers and vendors on messaging platforms, based on recent findings. Investigational Treatment Acquiring Traction Online The experimental drug, which remains in clinical trials, is being advertised by online personalities for its alleged weight-reducing properties. Followers are encouraged to contact these accounts directly for source information, while also receiving discount codes. Active Commerce on Social Networks Separately, a robust trade exists on messaging services, where groups with thousands of participants share “before and after” images, administration instructions and claims of next-day British shipping. Sellers promote the substance there before redirecting buyers to WhatsApp for purchases. Learning About The Experimental Drug This medication is an experimental injection developed by US drugmaker Eli Lilly. The drug targets three intestinal hormones – glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide and pancreatic hormone. Preliminary studies indicate it could assist individuals lose up to 25% of their total weight. Nicknamed the “triple G”, the drug is being promoted digitally as the successor to Ozempic. Healthcare Professionals Express Worries However, physicians and chemists have cautions that the distribution of what remains an unapproved drug in the UK is worrisome and could result in users injecting substances of unknown origin. Some professionals stated the demand for retatrutide could be linked to the rising cost of approved weight loss treatments such as Mounjaro. Regulatory Position and Enforcement Selling retatrutide on TikTok or messaging apps is prohibited in the United Kingdom, as it is an unlicensed drug that cannot be marketed or supplied for personal consumption under the Human Medicines Regulations 2012. Some influencers attempt to sidestep the rules by calling to the substance as a “research chemical” or describing it as “not for human consumption”. The substance is not a controlled substance, but advertising and supply can still breach medicines, marketing, and customer laws, risking fines, prosecution or imprisonment. Platform Reaction and Material Elimination According to the social media company, the platform has taken down problematic content and prohibited associated hashtags and search suggestions. The company stated it was committed to keeping the platform safe and allocating resources in enhancing enforcement strategies. Digital Trading Operations Research also discovered communities with up to nine thousand members marketing the experimental drug using Telegram's integrated search feature, which functions like a online catalog. Entering “retatrutide” immediately displays groups with numerous of users, filled with photos of slimming results, glowing testimonials and step-by-step guides for preparing or administering at home. After moments of joining one community, a vendor shared WhatsApp details, where most transactions take place. The seller provided an instruction manual and guaranteed delivery within 48 hours. When asked whether the product was authentic, one vendor said: “You can’t be sure.” Another shared a image of a supposed laboratory certificate. None asked about body mass, medical conditions or past usage. Item Information and Pricing Within these groups, posts display black plastic parcels with postal service labels, stating to include fresh supplies. One message read: “It took eight of us to load them this morning.” Buyers can select between dry substance containers, mixed at residence with sterile water, or ready-to-use pens usually sold at 160 pounds for 20mg. When asked how long a pen should last, sellers give conflicting answers varying between a few weeks to “depends on your body”. Service Moderation and Safety Actions A spokesperson for the messaging service said it actively monitored dangerous content on its platform including material that encouraged the “misuse of controlled medications”. The company added that it removed “millions of pieces of harmful content each day”. Medical Professional Cautions “People are injecting materials they cannot confirm. Although the research behind this drug is valid, these online products may not contain what they claim,” stated Jason Murphy, the director of pharmaceutical services at Chemist4U. A medical professional of an online medical service linked the increase in interest to current cost increases for authorized weight-loss drugs such as Mounjaro. “With costs increasing, individuals are turning to online platforms. But fake treatments are extremely risky. You can’t be certain what’s inside or whether the conditions they were produced in was clean,” she explained. Her staff has previously seen patients injured by self-injection from unconfirmed suppliers. “We recognize the frustration, but purchasing from messaging apps or communication platforms is gambling with your well-being,” said Wyllie. “These materials could be impure or incorrectly dosed.” Producer Statement A representative from Eli Lilly said retatrutide was in third stage clinical trials and had not been evaluated or authorized by any government authority anywhere in the world. “Therefore at this time no one can market [it] for human use,” they explained, noting that any item “misleadingly claiming itself as a Lilly experimental substance not yet authorized … may subject patients to potentially significant medical dangers”.